Patents by Inventor Antitsa Dimitrova Stoycheva
Antitsa Dimitrova Stoycheva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952365Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 8, 2021Date of Patent: April 9, 2024Assignees: Aligos Therapeutics, Inc., Katholieke Universiteit LeuvenInventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Vladimir Serebryany, Antitsa Dimitrova Stoycheva, Dorothée Alice Marie-Eve Bardiot, Sandro Boland, Arnaud Didier Marie Marchand
-
Publication number: 20240109871Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 13, 2023Publication date: April 4, 2024Inventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
-
Publication number: 20240018126Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 5, 2023Publication date: January 18, 2024Inventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
-
Patent number: 11851422Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 6, 2022Date of Patent: December 26, 2023Assignees: Katholieke Universiteit LeuvenInventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
-
Patent number: 11845752Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 13, 2021Date of Patent: December 19, 2023Assignee: Aligos Therapeutics, Inc.Inventors: Sandrine Vendeville, Yannick Debing, Antitsa Dimitrova Stoycheva, Pierre Jean-Marie Bernard Raboisson
-
Patent number: 11787833Abstract: Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), Formula (II) and/or Formula (III), or a pharmaceutically acceptable salt of any of the foregoing.Type: GrantFiled: May 6, 2020Date of Patent: October 17, 2023Assignee: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Santhosh Kumar Thatikonda, Antitsa Dimitrova Stoycheva
-
Patent number: 11760764Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: GrantFiled: May 19, 2021Date of Patent: September 19, 2023Assignee: Aligos Therapeutics, Inc.Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
-
Patent number: 11760761Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: GrantFiled: August 12, 2021Date of Patent: September 19, 2023Assignee: Aligos Therapeutics, Inc.Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Jerome Deval, Cheng Liu, Qingling Zhang
-
Publication number: 20230140238Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 14, 2022Publication date: May 4, 2023Inventors: Dorothée Alice Marie-Eve Bardiot, Koen Vandyck, Sandro Boland, Antitsa Dimitrova Stoycheva, Arnaud Didier Marie Marchand, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman
-
Publication number: 20230093249Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 6, 2022Publication date: March 23, 2023Inventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
-
Publication number: 20230065527Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: ApplicationFiled: August 12, 2021Publication date: March 2, 2023Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Jerome Deval, Cheng Liu, Qingling Zhang
-
Publication number: 20230031213Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: ApplicationFiled: June 15, 2022Publication date: February 2, 2023Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Cheng Liu, Jerome Deval, David McGowan
-
Publication number: 20230002413Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: ApplicationFiled: May 19, 2021Publication date: January 5, 2023Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
-
Publication number: 20230002409Abstract: The present invention relates to macrocyclic pyridotriazine derivatives and the prodrugs thereof, and the pharmaceutically acceptable salts, solvates or polymorph thereof, and the use of such compounds as a medicament, in particular in the prevention and/or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, and to the compositions or preparations for use as a medicament, more preferably for the prevention or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family.Type: ApplicationFiled: March 15, 2022Publication date: January 5, 2023Inventors: Robert Than HENDRICKS, Antitsa Dimitrova STOYCHEVA, Jean-François BONFANTI, Pierre Jean-Marie Bernard RABOISSON, Jérôme Michel Claude FORTIN, Guillaume Jean Maurice MERCEY
-
Patent number: 11312727Abstract: The present invention relates to macrocyclic pyridotriazine derivatives of formula (I) and the pharmaceutically acceptable salts, solvates or polymorph thereof, and the use of such compounds as a medicament, in particular in the prevention and/or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, and to the compositions or preparations for use as a medicament, more preferably for the prevention or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family.Type: GrantFiled: October 9, 2019Date of Patent: April 26, 2022Assignee: Janssen BioPharma, Inc.Inventors: Robert Than Hendricks, Antitsa Dimitrova Stoycheva, Jean-François Bonfanti, Pierre Jean-Marie Bernard Raboisson, Jérôme Michel Claude Fortin, Guillaume Jean Maurice Mercey
-
Publication number: 20220119395Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 13, 2021Publication date: April 21, 2022Inventors: Sandrine Vendeville, Yannick Debing, Antitsa Dimitrova Stoycheva, Pierre Jean-Marie Bernard Raboisson
-
Publication number: 20220009903Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 8, 2021Publication date: January 13, 2022Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Vladimir Serebryany, Antitsa Dimitrova Stoycheva, Dorothée Alice Marie-Eve Bardiot, Sandro Boland, Arnaud Didier Marie Marchand
-
Publication number: 20210186969Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.Type: ApplicationFiled: February 25, 2021Publication date: June 24, 2021Applicant: Janssen BioPharma, Inc.Inventors: Robert Than HENDRICKS, Leonid BEIGELMAN, David Bernard SMITH, Antitsa Dimitrova STOYCHEVA
-
Patent number: 10980805Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.Type: GrantFiled: August 9, 2019Date of Patent: April 20, 2021Assignee: Janssen BioPharma, Inc.Inventors: Robert Than Hendricks, Leonid Beigelman, David Bernard Smith, Antitsa Dimitrova Stoycheva
-
Publication number: 20210040483Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? position(s) along with methods of making and use, e.g., against HBV are disclosed.Type: ApplicationFiled: October 5, 2020Publication date: February 11, 2021Applicant: Janssen Biopharma, Inc.Inventors: Sergei GRYAZNOV, Leonid BEIGELMAN, Antitsa Dimitrova STOYCHEVA, Saul MARTINEZ MONTERO, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI, Lakshmipathi PANDARINATHAN, Yi JIN, Bharat BARAL